Effect of Leuprolide and Cetrorelix on Cell Growth, Apoptosis, and GnRH Receptor Expression in Primary Cell Cultures from Human Prostate Carcinoma

REFERENCES

• Cunha G. R., Donjacour A. A., Cooke P. S., Mee S., Bigsby R. M., et al. The endocrinology and developmental biology of the prostate. Endocr. Rev. 1987; 8: 338–362, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wilding G. The importance of steroid hormones in prostate cancer. Cancer. Surv. 1992; 14: 113–130, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Schally A., Comaru-Schally A., Gonzalez-Barcena D. Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer. Biomed. Pharmacother. 1992; 46(10)465–471, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fekete M., Redding T., Comaru-Scahlly A., Pontes J., Connelly R., et al. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate 1989; 14(3)191–208, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lamharzi N., Halmos G., Armatis P., Schally A. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int. J. Oncol. 1998; 12(3)671–675, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Halmos G., Arencibia J. M., Schally V., Davis R., Bostwick D. G. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J. Urol. 2000; 163(2)623–629, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Neil J. D. GnRH and GnRH receptor genes in the human genome. Endocrinology 2002; 143(3)737–743, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• McArdle C. A., Franklin J., Green L., Hislop J. N. Signaling, cycling and desensitisation of gonadotropin-releasing hormone receptors. J. Endocrinol. 2002; 173(1)1–11, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dondi D., Limonta P., Moretti R., Marelli M., Garattini E., et al. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res. 1994; 54(15)4091–4095, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Moretti R., Marelli M., Dondi D., Poletti A., Martini L., et al. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J. Clin. Endocrinol. Metab. 1996; 81(11)3930–3937, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Limonta P., Dondi D., Moretti R., Maggi R., Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J. Clin. Endocrinol. Metab. 1992; 75(1)207–212, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Redding T., Schally A., Radulovic S., Milovanovic S., Szapeshazi K., et al. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res. 1992; 52(9)2538–2544, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pinski I., Reile H., Halmos G., Groot K., Schally A. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int. J. Cancer 1994; 59(1)551–555, [CSA]
   Google Scholar
• Gonzalez-Barcena D., Vadillo-Buenfil M., Gomez-Orta F., Fuentes-Garcia M., Cardenas-Cornejo, et al. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994; 24(2)84–92, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Habenicht U. F., Schneider M. R., el Etreby M. F. Effect of the new potent LHRH antagonist antide. J. Steroid. Biochem. Mol. Biol. 1990; 37(6)937–942, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bhere H., Bockers A., Schlingheider A., Nieschlag E. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men. Clin. Endocrinol. (oxf) 1994; 40(2)241–248, [CSA]
   PubMed Web of Science ®Google Scholar
• Srkalovic G., Bokser L., Radulovic S., Korkut E., Schally A. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. Endocrinology 1990; 127(6)3052–3060, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Halmos G., Schally A., Vinski J., Vadillo-Buenfil M., Groot K. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc. Natl. Acad. Sci. USA 1996; 93(6)2398–2402, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Franklin J., Hislop J., Flynn A., McArdle C. A. Signaling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus. J. Endocrinol. 2003; 176(2)275–284, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Castellón E., Venegas K., Sáenz L., Contreras H., Huidobro C. Secretion of prostatic specific antigen, proliferative activity and androgen response in epithetial–stromal co-cultures from human prostatic carcinoma. Int. J. Androl. 2005; 28(1)39–46, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gleason D. F., Mellinger G. T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 1974; 111(1)58–64, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Israeli R. S., Powell C. T., Fair W. R., Heston W. D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993; 53(2)227–230, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Su Z. Z., Lin J., Shen R., Fisher P. E., Goldstein N. I., et al. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc. Natl. Acad. Sci. USA 1996; 93(14)7252–7257, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Limonta P., Moretti R. M., Marelli M. M., Dondi D., Parenti M., et al. The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 1999; 140(11)5250–5256, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kakar S. S., Grizzle W. E., Neill J. D. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol. Cell Endocrinol. 1994; 106(1–2)145–149, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Halmos G., Rekasi Z., Szoke B., Schally A. V. Used of radioreceptor assay and cell suerfusion system for in vitro screening of analogs of growth hormone-releasing hormone. Receptor 1993; 3: 87–97, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72: 248–254, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D., Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res. 1987; 47(4)943–946, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Singh N. P. Microgels for estimation of DNA strand breaks, DNA protein crosslinks and apoptosis. Mutat. Res. 2000; 455(1–2)111–127, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cunha G. R., Hayward S. W., Wang Y. Z., Ricke W. A. Role of the stromal microenvironment in carcinogenesis of the prostate. Int. J. Cancer 2003; 107(1)1–10, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Wong Y. C., Wang Y. Z. Growth factors and epithelial-stromal interactions in prostate cancer development. Int. Rev. Cytol. 2000; 199: 65–116, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kovacs M., Schally A. V. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats. Proc. Natl. Acad. Sci. USA 2001; 98(21)12197–12202, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Limonta P., Moretti R. M., Marelli M. M., Motta M. The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front. Neuroendocrinol. 2003; 24(4)279–295, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Moretti R. M., Marelli M. M., van Groeninghen J. C., Motta M., Limonta P. Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. Endocr. Relat. Cancer 2003; 10(2)161–167, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sica G., Iacopino F., Settesoldi D., Zelano G. Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells. Eur. Urol. 1999; 35(Suppl. 1)2–8, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Chatzaki E., Bax C. M., Eidne K. A., Anderson L., Grudzinskas J. G., et al. The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Cancer Res. 1996; 56(9)2059–2065, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ravenna L., Salvatori L., Morrone; S., Lubrano C., Cardillo M. R., et al. Effect of Triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP. J. Androl. 2000; 21(4)549–557, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar